Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies

Century Therapeutics Inc IPSC and Bristol Myers Squibb Co BMY have announced a research collaboration and license agreement for up to four induced pluripotent stem cell (iPSC) programs for hematologic malignancies and solid tumors. 

  • The first two programs include a program in acute myeloid leukemia and a program in multiple myeloma, which could incorporate either the iNK or a gamma delta iT platform. 
  • Bristol Myers Squibb has the option to add two additional programs.
  • Century will be responsible for development candidate discovery and preclinical development activities. 
  • After that, Bristol Myers Squibb will be responsible for clinical development and commercialization subject to Century's co-promotion rights on certain programs. 
  • Century will receive a $100 million upfront payment, and Bristol Myers Squibb will make a $50 million equity investment in Century Therapeutics' common stock at $23.14 per share. 
  • In addition, Century will receive reimbursement of certain preclinical development costs and is eligible for additional milestone payments totaling more than $3 billion across the four potential programs.
  • Price Action: IPSC shares are up 17.10% at $15.48, and BMY stock is up 0.37% at $63.06 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsSmall CapMoversTrading IdeasGeneralBriefswhy its moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!